TY - JOUR
T1 - Relugolix in Clinical Practice
T2 - The Best Route for All?
AU - Cordes, Lisa M.
AU - Karzai, Fatima
AU - Figg, William D.
AU - Madan, Ravi A.
N1 - Publisher Copyright:
© 2023 Wiley-Blackwell. All rights reserved.
PY - 2023/8
Y1 - 2023/8
N2 - Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.
AB - Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.
UR - http://www.scopus.com/inward/record.url?scp=85166468372&partnerID=8YFLogxK
U2 - 10.1093/oncolo/oyad099
DO - 10.1093/oncolo/oyad099
M3 - Review article
C2 - 37162497
AN - SCOPUS:85166468372
SN - 1083-7159
VL - 28
SP - 647
EP - 650
JO - Oncologist
JF - Oncologist
IS - 8
ER -